Portfolio data

Browse all portfolio data news

    Latest portfolio data news

    Show news from

    Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease

    Resolution Therapeutics to host virtual R&D webinar alongside world leading clinical hepatologists Prof. Jonathan Fallowfield and Dr. Elliot Tapper

    Resolution Therapeutics Announces First Patient Dosed and Safety Review Cleared in EMERALD Phase 1/2 Clinical Study of RTX001, a First-in-Class Regenerative Macrophage Therapy to Treat End-Stage Liver Disease

    Beacon Therapeutics completes enrolment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP

    Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)

    OMass Therapeutics to Present New Preclinical Data For its Best-in-Class MC2 Program at ENDO 2025

    Load more

    Search